For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Asia-Pacific hyperphosphatemia drugs market was worth $xx million in 2018. The market is estimated to grow at a CAGR of 17.37% during the forecast period of 2019-2027 and generate $xx million by the end of 2027. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. The growing prevalence of such chronic diseases, increasing elderly population, unmet medical attention, and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market in this region. The Asia-Pacific regions are expected to further propel the growth of the market in the coming years.
Increased cases of osteoporosis in the ageing population are observed in the Asia-Pacific regions, which are mostly going undertreated and underdiagnosed. This lapse is majorly responsible for the demand of the hyperphosphatemia drugs market in the Asian countries. The Indian hyperphosphatemia drugs market is growing with the highest CAGR of xx% during the forecast period. Growing elderly population in India is the key driving factor responsible for increasing the demand of the hyperphosphatemia drugs market in this region. The hyperphosphatemia drug market is segmented on the basis of the drug formulation. They include iron-based phosphate binders, calcium-based phosphate binders, magnesium-based phosphate binders, aluminium-based phosphate binders, and other phosphate binders. The Calcium-based phosphate binder's formulation is expected to lead the hyperphosphatemia drugs market during the forecast years. The Aluminium-based phosphate binders generated a revenue of $xx million in 2018 and are widely being used for the treatment of hyperphosphatemia in dialysis patients. The magnesium-based phosphorus binders are another widely used phosphorus binders, which also are remarkably being engaged in curing the hyperphosphatemia conditions in all the dialysis patients.
The major players in the hyperphosphatemia drug market are Johnson And Johnson, Cipla, Dsm, Biotech Pharmacal, Sun Pharm Inc, Zeria Pharmaceutical, Ultragenyx, Bruno Farmaceutici Spa, Fermenta Biotech Ltd, Fresenius Medical Care Pfizer Inc, Roche Diagnostics Corporation, Keryx Biopharmaceuticals , R.H. Moore Drug Co, Vifor Pharma, Sanofi, and Amag Pharmaceuticals.